Skip to content
GLP-1 Desk
Menu
Dispatch #225

Arc-1

Arc-1 offers compounded semaglutide (from $249.99) and compounded tirzepatide (from $299.99) as per-dose purchases, not monthly subscriptions.

Visit Arc-1Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way.
Semaglutide
$200/mo (0.5 mg dose, compounded)
Tirzepatide
$200/mo (2.5 mg dose, compounded)
Coverage
Coverage not published
Brand-name
Compounded only

Weigh Arc-1 against the full ranked field on the best semaglutide providers board, or line it up against its closest alternatives. Or go one-on-one: Arc-1 vs CoreAge Rx. Because Arc-1 dispenses compounded medication, it’s worth understanding whether compounded GLP-1 is legit and safe.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency86/100
State access24/100
Molecule range72/100
Onboarding speed70/100
Support responsiveness65/100
Licensing & trust63/100

What the Desk likes

  • Both compounded semaglutide and tirzepatide available
  • Per-dose purchasing — no subscription or membership required
  • 25% off plus free shipping promotion
  • Broader longevity formulary (rapamycin, NAD+, sermorelin)
  • LegitScript Certified badge now displayed on product pages

Where points come off

  • No legal entity name or address disclosed
  • State availability not disclosed
  • No named clinicians or pharmacy partners
  • Per-dose pricing still climbs with dose (semaglutide 2.5mg is $549.99/mo, tirzepatide 7.5mg $399.99/mo)

The Desk's briefing — C

Best for: Patients seeking per-dose compounded GLP-1 without subscriptions.

Arc-1 ranks #225 of 498 providers scored — see #1, CoreAge Rx on the board.

Related dispatches

Everyone else on the board (22)

Pricing and verification reflect Arc-1's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Arc-1's site. Not medical advice; see our disclosure.

← Back to The Desk